Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCTXNASDAQ:HILSNASDAQ:LMDXNASDAQ:LSTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXBriaCell Therapeutics$4.46-2.8%$4.09$3.00▼$36.60$17.03M1.34480,183 shs448,029 shsHILSHillstream BioPharma$1.36+13.3%$1.36$0.19▼$2.65$23.94M3.081.39 million shs1.92 million shsLMDXLumiraDx$0.01$0.02▼$1.33$5.10M1.7356.75 million shs132.24 million shsLSTALisata Therapeutics$2.37-3.3%$2.25$1.87▼$4.20$20.43M121,306 shs6,035 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXBriaCell Therapeutics-2.83%-17.86%+22.19%-19.93%-86.30%HILSHillstream BioPharma0.00%+16.27%-3.55%-31.66%+275.69%LMDXLumiraDx0.00%0.00%0.00%0.00%0.00%LSTALisata Therapeutics-1.66%+0.85%+0.85%-8.49%-13.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCTXBriaCell Therapeutics1.5891 of 5 stars3.52.00.00.01.60.00.6HILSHillstream BioPharmaN/AN/AN/AN/AN/AN/AN/AN/ALMDXLumiraDxN/AN/AN/AN/AN/AN/AN/AN/ALSTALisata Therapeutics2.9597 of 5 stars3.55.00.00.02.50.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTXBriaCell Therapeutics 3.00Buy$32.00617.49% UpsideHILSHillstream BioPharma 0.00N/AN/AN/ALMDXLumiraDx 0.00N/AN/AN/ALSTALisata Therapeutics 3.00Buy$15.00532.91% UpsideCurrent Analyst Ratings BreakdownLatest LMDX, LSTA, HILS, and BCTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/22/2025BCTXBriaCell TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.002/3/2025BCTXBriaCell TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $32.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTXBriaCell TherapeuticsN/AN/AN/AN/A($2.20) per shareN/AHILSHillstream BioPharmaN/AN/AN/AN/A$0.48 per shareN/ALMDXLumiraDx$126.52M0.00N/AN/A($0.33) per share0.00LSTALisata Therapeutics$1M20.43N/AN/A$5.88 per share0.40Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTXBriaCell Therapeutics-$4.79M-$5.03N/AN/AN/AN/AN/A-191.19%6/13/2025 (Estimated)HILSHillstream BioPharma-$8.47M-$0.72N/AN/AN/AN/A-188.44%-149.61%N/ALMDXLumiraDx-$447.79M-$1.09N/AN/AN/A-268.45%N/A-77.91%N/ALSTALisata Therapeutics-$20.84M-$2.40N/AN/AN/AN/A-51.19%-45.16%5/8/2025 (Estimated)Latest LMDX, LSTA, HILS, and BCTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025LSTALisata Therapeutics-$0.53N/AN/AN/AN/AN/A3/17/2025Q2 2025BCTXBriaCell Therapeutics-$1.94-$2.33-$0.39-$2.33N/AN/A2/27/2025Q4 2024LSTALisata Therapeutics-$0.76-$0.55+$0.21-$0.55N/A$1.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTXBriaCell TherapeuticsN/AN/AN/AN/AN/AHILSHillstream BioPharmaN/AN/AN/AN/AN/ALMDXLumiraDxN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTXBriaCell TherapeuticsN/A1.651.65HILSHillstream BioPharmaN/A3.013.01LMDXLumiraDxN/A0.450.23LSTALisata TherapeuticsN/A8.038.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTXBriaCell Therapeutics15.42%HILSHillstream BioPharma13.36%LMDXLumiraDx9.59%LSTALisata Therapeutics8.94%Insider OwnershipCompanyInsider OwnershipBCTXBriaCell Therapeutics5.73%HILSHillstream BioPharma30.24%LMDXLumiraDx35.41%LSTALisata Therapeutics9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTXBriaCell Therapeutics83.71 million3.50 millionOptionableHILSHillstream BioPharma117.60 million12.28 millionNot OptionableLMDXLumiraDx1,210318.55 million205.75 millionNot OptionableLSTALisata Therapeutics308.62 million7.63 millionNot OptionableLMDX, LSTA, HILS, and BCTX HeadlinesRecent News About These CompaniesLisata Therapeutics talks ADC breakthrough with Catalent – ICYMIApril 19, 2025 | proactiveinvestors.comLisata, Catalent partner for cancer drug researchApril 17, 2025 | uk.investing.comLisata Therapeutics signs research license with CatalentApril 15, 2025 | proactiveinvestors.comLisata Therapeutics Announces Research License with CatalentApril 15, 2025 | globenewswire.comLisata Therapeutics CEO discusses AI drug discovery collaboration - ICYMIMarch 8, 2025 | proactiveinvestors.comLisata Therapeutics And GATC Health Partner To Accelerate Drug Development Using AI TechnologyMarch 7, 2025 | nasdaq.comLisata Therapeutics to Present at the Investival Showcase USAMarch 6, 2025 | globenewswire.comLisata Therapeutics, GATC Health consummate first step in collaborationMarch 5, 2025 | markets.businessinsider.comLisata Therapeutics partners with GATC Health to advance AI-driven drug developmentMarch 5, 2025 | proactiveinvestors.comLisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug DevelopmentMarch 5, 2025 | globenewswire.comLisata Therapeutics’ Earnings Call: Progress Amid ChallengesFebruary 28, 2025 | tipranks.comLisata Therapeutics Inc (LSTA) Q4 2024 Earnings Call Highlights: Promising Developments Amid ...February 28, 2025 | finance.yahoo.comLisata Therapeutics, Inc. (LSTA) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | seekingalpha.comLisata Therapeutics exploring certepetide’s versatility in non-cancerous settingFebruary 27, 2025 | markets.businessinsider.comLisata Therapeutics CEO: 2025 to be ‘data-rich' as certepetide trials progressFebruary 27, 2025 | proactiveinvestors.comLisata Therapeutics CEO: 2025 to be ‘data-rich' as certepetide trials progressFebruary 27, 2025 | proactiveinvestors.comLisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateFebruary 27, 2025 | globenewswire.comLisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025February 20, 2025 | globenewswire.comLisata Therapeutics to Present at the 2025 BIO CEO & Investor ConferenceFebruary 5, 2025 | markets.businessinsider.comLisata Therapeutics CEO discusses recent pancreatic cancer trial milestones – ICYMIJanuary 25, 2025 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLMDX, LSTA, HILS, and BCTX Company DescriptionsBriaCell Therapeutics NASDAQ:BCTX$4.46 -0.13 (-2.83%) As of 04/30/2025 04:00 PM EasternBriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Hillstream BioPharma NASDAQ:HILS$1.36 +0.16 (+13.34%) As of 04/28/2025Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.LumiraDx NASDAQ:LMDXLumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.Lisata Therapeutics NASDAQ:LSTA$2.37 -0.08 (-3.27%) As of 04/30/2025 04:00 PM EasternLisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
